Our High-affinity Antibody Discovery Platform, on which we have developed LP-003, and another high-affinity antibody with high level of affinity on other targets, produces antibodies with significantly improved affinities that surpass traditional methods.
With a proven track record, our High-affinity Antibody Discovery Platform has already developed several picomolar blocking monoclonal antibodies, including our LP-003 with a KD of 2.08 pM and a high-affinity antibody with a KD of 2.33 pM. Additionally, we acquired a set of antibodies with comparable high-affinity levels.
| Target | High-affinity Antibody Discovery Platform | Competitors |
|---|---|---|
| IgE | 2.08 pM | 1780 pM |
We have established a novel Bi-functional Antibody Development Platform leveraging our proprietary antibody discovery and protein engineering technologies. This platform focuses on the development of differentiated bi-functional antibody biologics, with a view to addressing the limited therapeutic efficacy of single-target drugs, as well as the heightened costs, long duration and heavy patient burden associated with developing drugs targeting multiple pathways.
Our bi-functional antibody development strategy offers structural flexibility, broad applicability, and high druggability, extending beyond traditional antibody formats to include nanobodies, antibody fragments, receptors, regulatory proteins, and engineered Fc. This platform can be widely applied to generate various bi-functional antibodies, which will help us implement new treatment strategies in the fields of allergic and autoimmune diseases.
NeXineTM is the next-generation long-acting cytokine technology platform independently developed by Longbio Pharma.
The platform is based on the co-founder, Dr. Sun’s fc-fusion protein technology, and multiple candidate cytokine drug molecules have been developed based on this platform.
Dosing interval of Long acting cytokine that developed
by
NeXineTM platform
| Cytokine | NeXineTM | Competitors (Long-acting) |
|---|---|---|
| Growth hormone (GH) | Q2W-Q4W | Q1W |
| Erythropoietin (EPO) | Q4W | Q2W-Q3W |
| Insulin | Q2W | QD |
| Coagulation factor VIII | Q1W-Q2W | BIW |